Identification
- Summary
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used in the management of type 2 diabetes mellitus.
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo
- Generic Name
- Dapagliflozin
- DrugBank Accession Number
- DB06292
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2.3 When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria.1 Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.4
Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.12 It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.12
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Dapagliflozin (DB06292)
- Weight
- Average: 408.873
Monoisotopic: 408.133966239 - Chemical Formula
- C21H25ClO6
- Synonyms
- (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
- Dapagliflozin
- Dapagliflozina
- External IDs
- BMS 512148
- BMS-512148
Pharmacology
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.9,1,2For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.9 Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.9 Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.7,8 Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.7,8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Cardiovascular mortality •••••••••••• ••••• •••••• Prevention of Cardiovascular mortality •••••••••••• ••••• •••• •••• ••• ••••••••••• •• •••••• ••••••• •••••• Prevention of End stage renal disease (esrd) •••••••••••• ••••• •••• •••• ••• ••••••••••• •• •••••• ••••••• •••••• Prevention of Hospitalizations •••••••••••• ••••• ••••••••••••••• •••• •••••••• •••• • •••••••• •••••••• •••••• Prevention of Hospitalizations •••••••••••• ••••• •••• • •••••••• ••••••••• ••••••••••• •••••••••••••• ••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.10
Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. Dapagliflozin doses of 5 or 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12. A near-maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume. After discontinuation of dapagliflozin, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for the 10 mg dose.10
Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15 times the recommended maximum dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500 mg (50 times the recommended maximum dose) of dapagliflozin in healthy subjects.10
- Mechanism of action
Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.1 SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.1 This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.1
Target Actions Organism ASodium/glucose cotransporter 2 antagonistinhibitorHumans - Absorption
Oral dapagliflozin reaches a maximum concentration within 1 hour of administration when patients have been fasting.1 Following oral administration of dapagliflozin, the maximum plasma concentration (Cmax) is usually attained within 2 hours under fasting state. The Cmax and AUC values increase dose proportionally with an increase in dapagliflozin dose in the therapeutic dose range. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. Administration of dapagliflozin with a high-fat meal decreases its Cmax by up to 50% and prolongs Tmax by approximately 1 hour but does not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful and dapagliflozin can be administered with or without food.10
- Volume of distribution
The volume of distribution was estimated to be 118L.2
- Protein binding
Dapagliflozin is approximately 91% protein bound. Protein binding is not altered in patients with renal or hepatic impairment.10
- Metabolism
Dapagliflozin is primarily glucuronidated to become the inactive 3-O-glucuronide metabolite(60.7%).1,2 Dapagliflozin also produces another minor glucuronidated metabolite(5.4%), a de-ethylated metabolite(<5%), and a hydroxylated metabolite(<5%)1. Metabolism of dapagliflozin is mediated by cytochrome p-450(CYP)1A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP3A4, uridine diphosphate glucuronyltransferase(UGT)1A9, UGT2B4, and UGT2B72. Glucuronidation to the major metabolite is mediated by UGT1A9.2
Hover over products below to view reaction partners
- Route of elimination
Dapagliflozin and related metabolites are primarily eliminated via the renal pathway. Following a single 50 mg dose of [14C]-dapagliflozin, 75% and 21% of total radioactivity is excreted in urine and feces, respectively. In urine, less than 2% of the dose is excreted as the parent drug. In feces, approximately 15% of the dose is excreted as the parent drug.10
- Half-life
The mean plasma terminal half-life (t1/2) for dapagliflozin is approximately 12.9 hours following a single oral dose of 10 mg.10 In healthy subjects given a single oral dose of 50 mg of dapagliflozin, the mean terminal half-life was 13.8 hours.1
- Clearance
Oral plasma clearance was 4.9 mL/min/kg, and renal clearance was 5.6 mL/min.1
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Age, gender, race, and body weight do not affect dapagliflozin dosing requirementsLabel,2. Although age does not affect dosing requirements, safety has not been established in pediatric populations and patients at an especially advanced age may be more susceptible to adverse effectsLabel. Animal studies in pregnancy showed no fetal toxicity in the first trimester but exposure later in pregnancy was associated with renal pelvic dilatation and maternal toxicity at much higher doses than the maximum recommended human doseLabel. Due to this data, dapagliflozin is not recommended in the second and third trimester of pregnancyLabel. Dapagliflozin is excreted in milk from rats, though this may not necessarily be the case in humansLabel. Children under 2 years old who are exposed to dapagliflozin may be at risk of improper kidney developmentLabel. Dapagliflozin is not recommended in patients with a creatinine clearance below 45mL/min and is contraindicated in patients with creatinine clearance below 30mL/minLabel. Dose adjustments are not necessary in patients with hepatic impairment at any stage, although the risk and benefit to the patient must be assessed as there is limited data on dapagliflozin use in this populationLabel.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Abaloparatide is combined with Dapagliflozin. Acarbose Dapagliflozin may increase the hypoglycemic activities of Acarbose. Acebutolol The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acetazolamide. Acetohexamide Dapagliflozin may increase the hypoglycemic activities of Acetohexamide. - Food Interactions
- Avoid excessive or chronic alcohol consumption. Binge drinking or drinking alcohol often may predispose patients to ketoacidosis.
- Take with or without food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Dapagliflozin propanediol monohydrate 887K2391VH 960404-48-2 GOADIQFWSVMMRJ-UPGAGZFNSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dapagliflozin Viatris Tablet, film coated 5 mg Oral Viatris Limited 2023-04-04 Not applicable EU 
Dapagliflozin Viatris Tablet, film coated 5 mg Oral Viatris Limited 2023-04-04 Not applicable EU Dapagliflozin Viatris Tablet, film coated 10 mg Oral Viatris Limited 2023-04-04 Not applicable EU Dapagliflozin Viatris Tablet, film coated 5 mg Oral Viatris Limited 2023-04-04 Not applicable EU Dapagliflozin Viatris Tablet, film coated 10 mg Oral Viatris Limited 2023-04-04 Not applicable EU - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Accel-dapagliflozin Tablet 10 mg Oral Accel Pharma Inc Not applicable Not applicable Canada 
Accel-dapagliflozin Tablet 5 mg Oral Accel Pharma Inc Not applicable Not applicable Canada Ag-dapagliflozin Tablet 10 mg Oral Angita Pharma Inc. 2023-05-15 Not applicable Canada Ag-dapagliflozin Tablet 5 mg Oral Angita Pharma Inc. 2023-05-15 Not applicable Canada Apo-dapagliflozin Tablet 10 mg Oral Apotex Corporation 2023-05-16 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Apo-dapagliflozin-metformin Dapagliflozin (5 mg) + Metformin hydrochloride (850 mg) Tablet Oral Apotex Corporation 2023-12-14 Not applicable Canada Apo-dapagliflozin-metformin Dapagliflozin (5 mg) + Metformin hydrochloride (1000 mg) Tablet Oral Apotex Corporation 2023-12-01 Not applicable Canada Auro-dapagliflozin / Metformin Dapagliflozin (5 mg) + Metformin hydrochloride (850 mg) Tablet Oral Auro Pharma Inc 2023-05-16 Not applicable Canada Auro-dapagliflozin / Metformin Dapagliflozin (5 mg) + Metformin hydrochloride (1000 mg) Tablet Oral Auro Pharma Inc 2023-05-16 Not applicable Canada Dapagliflozin and Metformin Hydrochloride Dapagliflozin propanediol monohydrate (10 mg/1) + Metformin hydrochloride (1000 mg/1) Tablet, film coated, extended release Oral Prasco, Llc 2024-01-03 Not applicable US 
Categories
- ATC Codes
- A10BK01 — Dapagliflozin
- A10BK — Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
- A10 — DRUGS USED IN DIABETES
- A — ALIMENTARY TRACT AND METABOLISM
- A10BD — Combinations of oral blood glucose lowering drugs
- A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
- A10 — DRUGS USED IN DIABETES
- A — ALIMENTARY TRACT AND METABOLISM
- A10BD — Combinations of oral blood glucose lowering drugs
- A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
- A10 — DRUGS USED IN DIABETES
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Alimentary Tract and Metabolism
- Benzene Derivatives
- Blood Glucose Lowering Agents
- Carbohydrates
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2A6 Substrates
- Cytochrome P-450 CYP2C9 Substrates
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Diuretics
- Drugs Used in Diabetes
- Glycosides
- Hypotensive Agents
- Oral Hypoglycemics
- P-glycoprotein substrates
- Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
- Sodium-Glucose Transport Proteins, antagonists & inhibitors
- Sodium-Glucose Transporter 2 Inhibitors
- UGT1A9 Substrates
- UGT2B7 substrates
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Phenolic glycosides
- Alternative Parents
- Diphenylmethanes / Hexoses / C-glycosyl compounds / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Secondary alcohols show 6 more
- Substituents
- Alcohol / Alkyl aryl ether / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Benzenoid / C-glycosyl compound / Chlorobenzene / Dialkyl ether / Diphenylmethane show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- aromatic ether, organochlorine compound, C-glycosyl compound (CHEBI:85078)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 1ULL0QJ8UC
- CAS number
- 461432-26-8
- InChI Key
- JVHXJTBJCFBINQ-ADAARDCZSA-N
- InChI
- InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
- IUPAC Name
- (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
- SMILES
- CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
References
- General References
- Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [Article]
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Paik J, Blair HA: Correction to: Dapagliflozin: A Review in Type 1 Diabetes. Drugs. 2019 Dec;79(18):2011. doi: 10.1007/s40265-019-01238-2. [Article]
- Anderson SL: Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014 Dec;5(6):242-54. doi: 10.1177/2042098614551938. [Article]
- FDA Drug Approval Package: Dapagliflozin [Link]
- FDA Approved Drug Products: Farxiga Dapagliflozin Oral Tablets [Link]
- FDA Approved Drug Products: Qtern (dapagliflozin/saxagliptin) tablets for oral use [Link]
- FDA Approved Drug Products: Xigduo XR (metformin hydrochloride/dapagliflozin) extended-release tablets for oral use [Link]
- FDA Approved Drug Products: FARXIGA® (dapagliflozin) tablets, for oral use (May 2023) [Link]
- FDA Approved Drug Products: FARXIGA® (dapagliflozin) tablets, for oral use (September 2023) [Link]
- FDA Approved Drug Products: FARXIGA (dapagliflozin) tablets, for oral use [Link]
- FDA Approves Treatment for Chronic Kidney Disease [Link]
- External Links
- KEGG Drug
- D08897
- PubChem Compound
- 9887712
- PubChem Substance
- 175427068
- ChemSpider
- 8063384
- BindingDB
- 20880
- 1488564
- ChEBI
- 85078
- ChEMBL
- CHEMBL429910
- ZINC
- ZINC000003819138
- PDBe Ligand
- LE6
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Dapagliflozin
- PDB Entries
- 8hez
- FDA label
- Download (1.22 MB)
- MSDS
- Download (62.4 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention BMD / Lupus Nephritis / SGLT2 Inhibitors 1 4 Active Not Recruiting Prevention Chronic Kidney Disease (CKD) / Metabolic Bone Disorder 1 4 Active Not Recruiting Prevention Lupus Nephritis / SGLT2 Inhibitors / Systemic Lupus Erythematosus 1 4 Active Not Recruiting Treatment Aortic Stenosis / Transcatether Aortic Valve Implantation 1 4 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 5 mg/1 Tablet Oral 10 mg Tablet Oral 5 mg Tablet, film coated Oral Tablet, coated Oral 10 mg Tablet, film coated Oral 10 mg Tablet, film coated Oral 5 mg Tablet, film coated Oral Tablet, coated Oral Tablet Oral Tablet, film coated, extended release Oral Tablet, extended release Oral Tablet, film coated, extended release Oral 10 mg Tablet, film coated, extended release Oral 5 mg Tablet, extended release Oral 1005.04 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8216180 Yes 2012-07-10 2028-07-12 US US8439864 Yes 2013-05-14 2028-09-25 US US6667061 Yes 2003-12-23 2020-11-25 US US6495164 No 2002-12-17 2020-05-25 US US6872700 No 2005-03-29 2020-01-14 US US6956026 No 2005-10-18 2018-01-07 US US7741269 No 2010-06-22 2018-01-07 US US9238076 Yes 2016-01-19 2024-10-15 US US8906851 Yes 2014-12-09 2027-02-18 US US7612176 Yes 2009-11-03 2025-10-13 US US8431685 Yes 2013-04-30 2025-10-13 US US8461105 Yes 2013-06-11 2025-10-13 US US8329648 Yes 2012-12-11 2027-02-18 US US7456254 Yes 2008-11-25 2025-12-30 US US7563871 Yes 2009-07-21 2024-10-15 US US6824822 Yes 2004-11-30 2023-04-09 US US6479065 No 2002-11-12 2020-08-10 US US7223440 Yes 2007-05-29 2022-03-03 US USRE44186 No 2013-04-30 2023-07-31 US US8628799 No 2014-01-14 2025-07-13 US US8685934 No 2014-04-01 2030-05-26 US US8501698 Yes 2013-08-06 2027-12-20 US US6414126 No 2002-07-02 2020-10-04 US US6515117 Yes 2003-02-04 2026-04-04 US US6936590 No 2005-08-30 2020-10-04 US US9198925 No 2015-12-01 2020-10-04 US US7919598 No 2011-04-05 2029-12-16 US US8361972 Yes 2013-01-29 2028-09-21 US US8716251 No 2014-05-06 2028-03-21 US US7851502 No 2010-12-14 2028-08-19 US US8221786 No 2012-07-17 2028-03-21 US US9616028 No 2017-04-11 2030-11-12 US US9320853 Yes 2016-04-26 2028-09-25 US US8827963 Yes 2014-09-09 2029-08-04 US US8712615 No 2014-04-29 2030-01-18 US US8998876 Yes 2015-04-07 2030-07-07 US US8758292 Yes 2014-06-24 2028-05-12 US US8690837 Yes 2014-04-08 2029-11-19 US US8721615 Yes 2014-05-13 2030-07-18 US US10973836 No 2021-04-13 2040-03-09 US US11826376 No 2019-07-18 2039-07-18 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 65 [MSDS] boiling point (°C) 609 [MSDS] logP 2.7 [MSDS] - Predicted Properties
Property Value Source Water Solubility 0.173 mg/mL ALOGPS logP 2.52 ALOGPS logP 2.11 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 12.57 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 99.38 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 104.93 m3·mol-1 Chemaxon Polarizability 42.88 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0004900000-37d5265038fa7c24626e Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2004900000-6928e6b6d57bec67ba2d Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4v-0189200000-93e1a5b8bad4db74540d Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9106100000-9a396305692d475c12d7 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4r-4397100000-1b671b635a693b641833 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-06si-5369100000-47981f8cfa2a05bfee8a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.7367 predictedDeepCCS 1.0 (2019) [M+H]+ 189.13226 predictedDeepCCS 1.0 (2019) [M+Na]+ 195.51756 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- AntagonistInhibitor
- General Function
- Low-affinity glucose:sodium symporter activity
- Specific Function
- Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
- Gene Name
- SLC5A2
- Uniprot ID
- P31639
- Uniprot Name
- Sodium/glucose cotransporter 2
- Molecular Weight
- 72895.995 Da
References
- Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
- Gene Name
- UGT1A9
- Uniprot ID
- O60656
- Uniprot Name
- UDP-glucuronosyltransferase 1-9
- Molecular Weight
- 59940.495 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
- Gene Name
- UGT2B4
- Uniprot ID
- P06133
- Uniprot Name
- UDP-glucuronosyltransferase 2B4
- Molecular Weight
- 60512.035 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
- Gene Name
- UGT2B7
- Uniprot ID
- P16662
- Uniprot Name
- UDP-glucuronosyltransferase 2B7
- Molecular Weight
- 60694.12 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Vitamin d 24-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A1
- Uniprot ID
- P04798
- Uniprot Name
- Cytochrome P450 1A1
- Molecular Weight
- 58164.815 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Forxiga Assessment report [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- Based on in vitro data with recombinant CYP isoforms
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [Article]
Drug created at March 19, 2008 16:22 / Updated at February 20, 2024 23:55